|
Gene: PTRH2 |
Gene summary for PTRH2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PTRH2 | Gene ID | 51651 |
Gene name | peptidyl-tRNA hydrolase 2 | |
Gene Alias | BIT1 | |
Cytomap | 17q23.1 | |
Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | J3KQ48 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51651 | PTRH2 | LZE4T | Human | Esophagus | ESCC | 7.40e-05 | 5.88e-02 | 0.0811 |
51651 | PTRH2 | LZE7T | Human | Esophagus | ESCC | 4.29e-03 | 3.97e-01 | 0.0667 |
51651 | PTRH2 | LZE8T | Human | Esophagus | ESCC | 2.61e-02 | -5.40e-03 | 0.067 |
51651 | PTRH2 | LZE20T | Human | Esophagus | ESCC | 3.43e-06 | -4.12e-02 | 0.0662 |
51651 | PTRH2 | LZE24T | Human | Esophagus | ESCC | 2.00e-06 | 4.00e-01 | 0.0596 |
51651 | PTRH2 | P1T-E | Human | Esophagus | ESCC | 9.01e-06 | 4.48e-01 | 0.0875 |
51651 | PTRH2 | P2T-E | Human | Esophagus | ESCC | 8.97e-12 | 2.04e-01 | 0.1177 |
51651 | PTRH2 | P4T-E | Human | Esophagus | ESCC | 2.80e-16 | 4.18e-01 | 0.1323 |
51651 | PTRH2 | P5T-E | Human | Esophagus | ESCC | 2.44e-22 | 2.43e-01 | 0.1327 |
51651 | PTRH2 | P8T-E | Human | Esophagus | ESCC | 1.29e-13 | 2.33e-01 | 0.0889 |
51651 | PTRH2 | P9T-E | Human | Esophagus | ESCC | 3.51e-15 | 4.67e-01 | 0.1131 |
51651 | PTRH2 | P10T-E | Human | Esophagus | ESCC | 1.03e-30 | 3.90e-01 | 0.116 |
51651 | PTRH2 | P11T-E | Human | Esophagus | ESCC | 7.26e-16 | 7.85e-01 | 0.1426 |
51651 | PTRH2 | P12T-E | Human | Esophagus | ESCC | 3.08e-24 | 2.55e-01 | 0.1122 |
51651 | PTRH2 | P15T-E | Human | Esophagus | ESCC | 6.23e-14 | 2.81e-01 | 0.1149 |
51651 | PTRH2 | P16T-E | Human | Esophagus | ESCC | 1.43e-17 | 3.40e-01 | 0.1153 |
51651 | PTRH2 | P17T-E | Human | Esophagus | ESCC | 1.25e-05 | 2.60e-01 | 0.1278 |
51651 | PTRH2 | P19T-E | Human | Esophagus | ESCC | 1.06e-06 | 3.74e-01 | 0.1662 |
51651 | PTRH2 | P20T-E | Human | Esophagus | ESCC | 3.93e-11 | 2.83e-01 | 0.1124 |
51651 | PTRH2 | P21T-E | Human | Esophagus | ESCC | 1.87e-19 | 5.49e-01 | 0.1617 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | |
Endometrium | AEH | |
Endometrium | EEC | |
Prostate | BPH | |
Prostate | Tumor |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20002093 | Esophagus | ESCC | regulation of anoikis | 20/8552 | 24/18723 | 1.69e-04 | 1.11e-03 | 20 |
GO:00432761 | Esophagus | ESCC | anoikis | 26/8552 | 34/18723 | 2.53e-04 | 1.55e-03 | 26 |
GO:20008113 | Esophagus | ESCC | negative regulation of anoikis | 14/8552 | 17/18723 | 2.22e-03 | 9.78e-03 | 14 |
GO:20008112 | Oral cavity | OSCC | negative regulation of anoikis | 15/7305 | 17/18723 | 4.02e-05 | 3.49e-04 | 15 |
GO:0043276 | Oral cavity | OSCC | anoikis | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
GO:20002092 | Oral cavity | OSCC | regulation of anoikis | 17/7305 | 24/18723 | 1.59e-03 | 7.56e-03 | 17 |
GO:00432762 | Thyroid | PTC | anoikis | 18/5968 | 34/18723 | 8.65e-03 | 3.62e-02 | 18 |
GO:20008114 | Thyroid | ATC | negative regulation of anoikis | 12/6293 | 17/18723 | 2.02e-03 | 9.60e-03 | 12 |
GO:004327611 | Thyroid | ATC | anoikis | 19/6293 | 34/18723 | 6.21e-03 | 2.48e-02 | 19 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTRH2 | SNV | Missense_Mutation | rs145040441 | c.44N>T | p.Pro15Leu | p.P15L | protein_coding | deleterious(0.05) | benign(0.059) | TCGA-C8-A12P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PTRH2 | SNV | Missense_Mutation | rs763966443 | c.218G>A | p.Arg73Gln | p.R73Q | protein_coding | deleterious(0.02) | possibly_damaging(0.889) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
PTRH2 | SNV | Missense_Mutation | novel | c.115N>T | p.Gly39Trp | p.G39W | protein_coding | deleterious(0.02) | benign(0.063) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
PTRH2 | SNV | Missense_Mutation | novel | c.107N>C | p.Val36Ala | p.V36A | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PTRH2 | SNV | Missense_Mutation | rs763966443 | c.218N>A | p.Arg73Gln | p.R73Q | protein_coding | deleterious(0.02) | possibly_damaging(0.889) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PTRH2 | SNV | Missense_Mutation | c.188N>T | p.Ser63Ile | p.S63I | protein_coding | tolerated(0.1) | benign(0.033) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PTRH2 | SNV | Missense_Mutation | novel | c.144N>C | p.Lys48Asn | p.K48N | protein_coding | tolerated(0.39) | benign(0.001) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PTRH2 | SNV | Missense_Mutation | novel | c.170N>A | p.Ala57Glu | p.A57E | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
PTRH2 | SNV | Missense_Mutation | novel | c.60N>T | p.Leu20Phe | p.L20F | protein_coding | tolerated(0.16) | benign(0.011) | TCGA-38-4626-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
PTRH2 | SNV | Missense_Mutation | novel | c.17N>G | p.Ser6Cys | p.S6C | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.819) | TCGA-56-A5DR-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |